Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Apalutamide in Subjects with Hepatic Impairment
NCT02524717Phase 1Completed
- Sponsor
- Aragon Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Feb 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apalutamide in prostate cancer (PCa), sponsored by Aragon Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration, Maximum Plasma Concentration Corrected for Unbound Fraction and 16 more. Started Aug 2015; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02524717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524717.